Prediction of treatment outcomes in patients with chest wall sarcoma: Evaluation with PET/CT

Japanese Journal of Clinical Oncology

Volumn 42, Issue 10, 2012, Pages 912-918

  Nishiyama, Yuji ^a   Tateishi, Ukihide ^a   Kawai, Akira ^b   Chuman, Hirokazu ^b   Nakatani, Fumihiko ^b   Miyake, Mototaka ^b   Terauchi, Takashi ^c   Inoue, Tomio ^a   Kim, Edmund E ^d  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Orthopedics sarcoma; Prognostic factors; Radiology PET CT

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; IFOSFAMIDE; KI 67 ANTIGEN; VINCRISTINE;

ADULT; AGED; ALVEOLAR SOFT PART SARCOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CHONDROSARCOMA; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DERMATOFIBROSARCOMA PROTUBERANS; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MEDICAL RECORD REVIEW; MYXOFIBROSARCOMA; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; SARCOMA; SURVIVAL PREDICTION; SYNOVIAL SARCOMA; THORAX WALL TUMOR; TREATMENT RESPONSE;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SARCOMA; SURVIVAL RATE; THORACIC NEOPLASMS; THORACIC WALL; YOUNG ADULT;

EID: 84866755862     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys116     Document Type: Article

References (19)

1. Weiss SW, Goldblum JR, editors. Enzinger and Weiss's Soft Tissue Tumours. 4th edn. St. Louis: Mosby 2001.
2. Walsh GL, Davis BM, Swisher SG, et al. A single-institutional, multidisciplinary approach to primary sarcomas involving the chest wall requiring full-thickness resections. J Thorac Cardiovasc Surg 2001;121:48-60.
3. Athanassiadi K, Kalavrouziotis G, Rondogianni D, Loutsidis A, Hatzimichalis A, Bellenis I. Primary chest wall tumors: early and long-term results of surgical treatment. Eur J Cardiothorac Surg 2001;19:589-93.
4. Shamberger RC, LaQuaglia MP, Gebhardt MC, et al. Ewing sarcoma/ primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 2003;238:563-7.
5. Hasegawa T, Yamamoto S, Yokoyama R, Umeda T, Matsuno Y, Hirohashi S. Prognostic significance of grading and staging system using MIB-1 score in adult patients with soft tissue sarcoma of the extremities and trunk. Cancer 2002;95:843-51.
6. Hasegawa T, Yamamoto S, Nojima T, et al. Validity and reproducibility of histologic diagnosis and grading for adult soft-tissue sarcomas. Hum Pathol 2002;33:111-5.
7. Tateishi U, Gladish GW, Kusumoto M, et al. Chest wall tumors: radiologic findings and pathologic correlation: part 2. Malignant tumors. Radiographics 2003;23:1491-508.
8. Nieweg OE, Prium J, van Ginkel RJ, et al. Fluorine-18 fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37:257-61.
9. Schwarzbach MHM, Dimitrakopoulou-Strauss A, Willeke F, et al. Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2000;231: 380-6.
10. Fary JF, Conrad EU, Bruckner JD, et al. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998;4:1214-20.
11. 18F-FDG PET for the diagnosis of soft tissue sarcoma: a meta-analysis. J Nucl Med 2003;44:717-24.
12. Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas: a systematic review and meta-analysis. Cancer Treat Rev 2004;30:83-101.
13. Folpe AL, Lyles RH, Sprouse JT, Conrad EU, III, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000;6:1279-87.
14. Benz RM, Czernin J, Allen-Auerbach MS, et al. FDG-PET/CT imaging predicts histopathologic treatment responses and after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2009;15:2856-63.
15. Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumor grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33:683-91.
16. Ito S, Nemoto T, Satoh S, Sekihara H, Seyama Y, Kubota S. Human rhabdomyosarcoma cells retain insulin-regulated glucose transport activity through glucose transporter 1. Arch Biochem Biophys 2000;3:72-82.
17. Fukukita H, Senda M, Terauchi T, et al. Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 1.0. Ann Nucl Med 2010;24:325-34.
18. Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press 2002.
19. Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biol Res 2002;35:9-26.